Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| Somatostatin receptor 2 Lower in grade 3 | 80-90% | SSTR PET positivity (well-differentiated) | Wikipedia |
| Tryptophan hydroxylase 1 | host% | Host target: serotonin synthesis in enterochromaffin cells. Not a tumour alteration, so no prevalence applies; the drug acts on normal tissue or on symptoms. |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.